Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

NCT00615602 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

489

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Trastuzumab
DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: 5-fluoruracil
DRUG: Granulocyte-colony stimulating growth factor
DRUG: Trastuzumab

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]